These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 18835393)

  • 1. Serial re-challenge with influenza vaccine as a tool to study individual immune responses.
    Vallerskog T; Gaines H; Feldman A; Culbert E; Klareskog L; Malmström V; Trollmo C
    J Immunol Methods; 2008 Dec; 339(2):165-74. PubMed ID: 18835393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Keeping the memory of influenza viruses.
    Combadière B; Sibéril S; Duffy D
    Pathol Biol (Paris); 2010 Apr; 58(2):e79-86. PubMed ID: 20303671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses.
    Engler RJ; Nelson MR; Klote MM; VanRaden MJ; Huang CY; Cox NJ; Klimov A; Keitel WA; Nichol KL; Carr WW; Treanor JJ;
    Arch Intern Med; 2008 Dec; 168(22):2405-14. PubMed ID: 19064822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity.
    Bakke H; Samdal HH; Holst J; Oftung F; Haugen IL; Kristoffersen AC; Haugan A; Janakova L; Korsvold GE; Krogh G; Andersen EA; Djupesland P; Holand T; Rappuoli R; Haneberg B
    Scand J Immunol; 2006 Mar; 63(3):223-31. PubMed ID: 16499576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus.
    Holvast A; van Assen S; de Haan A; Huckriede A; Benne CA; Westra J; Palache A; Wilschut J; Kallenberg CG; Bijl M
    Arthritis Rheum; 2009 Aug; 60(8):2438-47. PubMed ID: 19644961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrasting B cell- and T cell-based protective vaccines.
    Jansen VA; Altes HK; Funk GA; Wodarz D
    J Theor Biol; 2005 May; 234(1):39-48. PubMed ID: 15721034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel adjuvant CoVaccineHT increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro.
    Bodewes R; Geelhoed-Mieras MM; Heldens JG; Glover J; Lambrecht BN; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
    Vaccine; 2009 Nov; 27(49):6833-9. PubMed ID: 19772942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults.
    Leroux-Roels I; Van der Wielen M; Kafeja F; Vandermeulen C; Lazarus R; Snape MD; John T; Carre C; Nougarede N; Pepin S; Leroux-Roels G; Hoppenbrouwers K; Pollard AJ; Van Damme P
    Vaccine; 2009 Nov; 27(49):6918-25. PubMed ID: 19761837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole blood assessment of antigen specific cellular immune response by real time quantitative PCR: a versatile monitoring and discovery tool.
    Schultz-Thater E; Frey DM; Margelli D; Raafat N; Feder-Mengus C; Spagnoli GC; Zajac P
    J Transl Med; 2008 Oct; 6():58. PubMed ID: 18925935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
    Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and humoral systemic and mucosal immune responses stimulated in volunteers by an oral polybacterial immunomodulator "Dentavax".
    Petrunov B; Marinova S; Markova R; Nenkov P; Nikolaeva S; Nikolova M; Taskov H; Cvetanov J
    Int Immunopharmacol; 2006 Jul; 6(7):1181-93. PubMed ID: 16714223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of the kinesis of immune responses in mice vaccinated by different kinds of recombinant hepatitis B vaccines].
    Hu ZY; He P; Fang X; Qiu SH; Liang ZL; Li HM; Zhuang H
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug; 29(8):810-4. PubMed ID: 19103120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High preexisting serological antibody levels correlate with diversification of the influenza vaccine response.
    Andrews SF; Kaur K; Pauli NT; Huang M; Huang Y; Wilson PC
    J Virol; 2015 Mar; 89(6):3308-17. PubMed ID: 25589639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric virus-like particles for the delivery of an inserted conserved influenza A-specific CTL epitope.
    Cheong WS; Reiseger J; Turner SJ; Boyd R; Netter HJ
    Antiviral Res; 2009 Feb; 81(2):113-22. PubMed ID: 19007818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
    Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
    de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
    Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the potency, optimal antigen level and lasting immunity of inactivated avian influenza vaccine prepared from H5N1 virus.
    Sasaki T; Isoda N; Soda K; Sakamoto R; Saijo K; Hagiwara J; Kokumai N; Ohgitani T; Imamura T; Sawata A; Lin Z; Sakoda Y; Kida H
    Jpn J Vet Res; 2009 Feb; 56(4):189-98. PubMed ID: 19358446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.